[go: up one dir, main page]

ZA200805786B - Use of CNS penetrating anticancer compounds for the treatment of protozoal diseases - Google Patents

Use of CNS penetrating anticancer compounds for the treatment of protozoal diseases

Info

Publication number
ZA200805786B
ZA200805786B ZA200805786A ZA200805786A ZA200805786B ZA 200805786 B ZA200805786 B ZA 200805786B ZA 200805786 A ZA200805786 A ZA 200805786A ZA 200805786 A ZA200805786 A ZA 200805786A ZA 200805786 B ZA200805786 B ZA 200805786B
Authority
ZA
South Africa
Prior art keywords
treatment
anticancer compounds
protozoal diseases
cns penetrating
cns
Prior art date
Application number
ZA200805786A
Other languages
English (en)
Inventor
Dormeyer Matthias
Original Assignee
Dormeyer Matthias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dormeyer Matthias filed Critical Dormeyer Matthias
Publication of ZA200805786B publication Critical patent/ZA200805786B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200805786A 2006-01-12 2008-07-02 Use of CNS penetrating anticancer compounds for the treatment of protozoal diseases ZA200805786B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06000654A EP1808173A1 (en) 2006-01-12 2006-01-12 Use of CNS penetrating anticancer compounds for the treatment of protozan diseases

Publications (1)

Publication Number Publication Date
ZA200805786B true ZA200805786B (en) 2009-08-26

Family

ID=36061620

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805786A ZA200805786B (en) 2006-01-12 2008-07-02 Use of CNS penetrating anticancer compounds for the treatment of protozoal diseases

Country Status (5)

Country Link
US (1) US20110118199A1 (xx)
EP (2) EP1808173A1 (xx)
CA (1) CA2635825A1 (xx)
WO (1) WO2007080116A2 (xx)
ZA (1) ZA200805786B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2928035C (en) 2012-12-27 2024-07-02 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
CN104910069B (zh) * 2014-12-15 2018-03-23 北京科技大学 氨茴酸类衍生物、其制备方法及其在医药上的用途
JP7085485B2 (ja) 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー 分泌型p-糖タンパク質は、慢性鼻副鼻腔炎の非侵襲的バイオマーカーである
WO2017214468A1 (en) 2016-06-09 2017-12-14 Tien Yang Der Nanodroplet compositions for the efficient delivery of anti-cancer agents
CN108659001B (zh) * 2018-07-16 2020-01-31 陕西科技大学 一种氟哌噻吨衍生物及其制备方法
US12295933B2 (en) 2019-03-25 2025-05-13 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity
EP4574143A1 (en) * 2023-12-21 2025-06-25 Universität Regensburg Inhibitors of plasmodia remodeling enzymes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399151A (en) * 1980-06-16 1983-08-16 Merrell Dow Pharmaceuticals Inc. Method of inhibiting the growth of protozoa
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5101072A (en) * 1989-09-06 1992-03-31 Yale University Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents
US5631278A (en) * 1992-12-02 1997-05-20 Thomas Jefferson University Methods of killing protozoal parasites
FR2707165B1 (fr) * 1993-07-06 1995-08-11 Rhone Poulenc Rorer Sa Application des taxoides au traitement de maladies d'origine parasitaire .
US6703400B2 (en) * 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
AP2006003756A0 (en) * 2004-03-05 2006-10-31 He Regents Of The University O Anti-parasitic compounds and methods of their use
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺-8-羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途
CN1752088A (zh) * 2004-09-22 2006-03-29 天津市金士力药物研究开发有限公司 含有替莫唑胺酯的药用组合物

Also Published As

Publication number Publication date
WO2007080116A2 (en) 2007-07-19
CA2635825A1 (en) 2007-07-19
EP1971335A2 (en) 2008-09-24
WO2007080116A3 (en) 2007-11-29
EP1808173A1 (en) 2007-07-18
US20110118199A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
HUE043569T2 (hu) Vegyületek rák kezelésére
ZA201001304B (en) Compositions for the treatment of neoplastic diseases
IL195571A0 (en) Compounds for the treatment of periodontal disease
SI2118074T1 (sl) Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
ZA201100534B (en) Triazole derivatives useful for the treatment of diseases
IL200862A0 (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
ZA200805786B (en) Use of CNS penetrating anticancer compounds for the treatment of protozoal diseases
ZA200906129B (en) Compounds for the treatment of hepatitis c
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
ZA201001262B (en) Interval therapy for the treatment of tinnitus
PL2209784T3 (pl) Związki do leczenia zapalenia wątroby typu C
ZA201000923B (en) Compounds for the treatment of hepatitis c
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
PL2022504T3 (pl) Maść do leczenia hemoroidów
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
ZA201001546B (en) Isoxazole compounds for the treatment of cancer
IL205339A0 (en) Compounds and methods for the treatment of cancer
GB0602857D0 (en) The treatment of sialorrhoea
GB0715255D0 (en) Thiadiazol-piperazinyl derivatives for the treatment of neurodegenerative diseases